Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)
Open Access

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE

Jonathan R. Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, Edward M. Wolin, Beth R. Chasen, Matthew H. Kulke, David L. Bushnell, Martyn E. Caplin, Richard P Baum, Andrew E. Hendifar, Kjell Öberg, Philippe Ruszniewski, Paola Santoro, Per Broberg, Oscar R. Leeuwenkamp and Eric P. Krenning
Journal of Nuclear Medicine March 2021, jnumed.120.258897; DOI: https://doi.org/10.2967/jnumed.120.258897
Jonathan R. Strosberg
1 H. Lee Moffitt Cancer Center & Research Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajaventhan Srirajaskanthan
2 Neuroendocrine Tumour Unit, Department of Gastroenterology, King's College Hospital, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ghassan El-Haddad
3 H. Lee Moffitt Center & Research Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward M. Wolin
4 Center for Carcinoid and Neuroendocrine Tumors, Tish Cancer Institute at Mount Sinai, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beth R. Chasen
5 Department of Nuclear Medicine, Division of Diagnostic Imaging, MD Anderson Cancer Center, The University of Texas, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew H. Kulke
6 Section of Hematology and Medical Oncology, Boston University and Boston Medical Center, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Bushnell
7 Department of Radiology, University of Iowa, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martyn E. Caplin
8 Neuroendocrine Tumour Unit, Royal Free Hospital, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard P Baum
9 CURANOSTICUM Wiesbaden-Frankfurt, DKD HELIOS Clinic, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew E. Hendifar
10 Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kjell Öberg
11 Department of Medical Sciences, Uppsala University, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Ruszniewski
12 Division of Gastroenterology and Pancreatology, Hôpital Beaujon, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Santoro
13 Advanced Accelerator Applications, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Broberg
13 Advanced Accelerator Applications, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oscar R. Leeuwenkamp
14 Advanced Accelerator Applications,, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric P. Krenning
15 Cyclotron Rotterdam BV, Erasmus University Medical Center, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

We report the impact of 177Lu DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors (NETs) often find burdensome. Methods: All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial (177Lu-DOTATATE plus standard-dose octreotide long-acting repeatable [LAR], n = 117; high-dose octreotide LAR, n = 114) were asked to record the occurrence of predefined symptoms in a daily diary. Change from baseline in symptom scores (mean number of days with a symptom) was analyzed using a mixed model for repeated measures. Results: Patients (intent-to-treat) who received 177Lu-DOTATATE experienced a significantly greater decline from baseline in symptom scores than patients who received high-dose octreotide LAR. For 177Lu-DOTATATE, the mean decline in days with abdominal pain, diarrhea, and flushing was 4.10, 4.55, and 4.52 days per 4 weeks, respectively, compared with 0.99, 1.44, and 2.54 days for high-dose octreotide LAR. The mean differences were 3.11 days (95% confidence interval, 1.35–4.88; P = 0.0007) for abdominal pain, 3.11 days (1.18–5.04; P = 0.0017) for diarrhea, and 1.98 days (0.08–3.88; P = 0.0413) for flushing, favoring 177Lu-DOTATATE. A positive repeated measures correlation was found between diary-recorded symptom scores and questionnaire-recorded pain, diarrhea, and flushing. Conclusion: In addition to efficacy and quality of life benefits, symptom diaries from NETTER-1 demonstrated that treatment with 177Lu DOTATATE was associated with statistically significant reductions in abdominal pain, diarrhea, and flushing, constituting the core symptoms of patients with progressive midgut NETs, compared with high-dose octreotide LAR, supporting a beneficial effect of 177Lu DOTATATE on HRQoL.

  • Neuroendocrine
  • Oncology: Endocrine
  • Radionuclide Therapy
  • NETTER-1
  • lutetium-177
  • neuroendocrine
  • symptom diary
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (5)
Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE
Jonathan R. Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, Edward M. Wolin, Beth R. Chasen, Matthew H. Kulke, David L. Bushnell, Martyn E. Caplin, Richard P Baum, Andrew E. Hendifar, Kjell Öberg, Philippe Ruszniewski, Paola Santoro, Per Broberg, Oscar R. Leeuwenkamp, Eric P. Krenning
Journal of Nuclear Medicine Mar 2021, jnumed.120.258897; DOI: 10.2967/jnumed.120.258897

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE
Jonathan R. Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, Edward M. Wolin, Beth R. Chasen, Matthew H. Kulke, David L. Bushnell, Martyn E. Caplin, Richard P Baum, Andrew E. Hendifar, Kjell Öberg, Philippe Ruszniewski, Paola Santoro, Per Broberg, Oscar R. Leeuwenkamp, Eric P. Krenning
Journal of Nuclear Medicine Mar 2021, jnumed.120.258897; DOI: 10.2967/jnumed.120.258897
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: methodological and diagnostic implications for malignant, inflammatory and degenerative lesions
  • First-in-Human PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using 18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic
  • Safety and efficacy of holmium-166 radioembolization in hepatocellular carcinoma – the HEPAR Primary study
Show more Clinical Investigations (Human)

Clinical (Endocrine/Neuroendocrine)

  • Choice is good at times: the emergence of [64Cu]Cu-DOTATATE based somatostatin receptor imaging in the era of [68Ga]Ga-DOTATATE
  • Development of Flourinated NP-59: A Revival of Cholesterol Utilization Imaging with PET
  • Brown adipose tissue: a protective mechanism in “pre-prediabetes”?
Show more Clinical (Endocrine/Neuroendocrine)

Similar Articles

Keywords

  • Neuroendocrine
  • Oncology: Endocrine
  • Radionuclide Therapy
  • NETTER-1
  • lutetium-177
  • symptom diary
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire